Analysis Of Income And Expense [Abstract]

Marinomed Biotech AG - Filing #1079021

Concept	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31	2020-01-01 to 2020-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	11,628 EUR	—	—	—	8,124 EUR	—
Material income and expense [abstract]
Finance income (cost)	—	—	1,550 EUR	—	—	—	1,907,000 EUR	—
Expenses by nature [abstract]
Raw materials and consumables used	—	—	6,428 EUR	—	—	—	5,414 EUR	—
Services expense	—	—	3,775 EUR	—	—	—	3,352 EUR	—
Classes of employee benefits expense [abstract]
Employee benefits expense	—	—	4,462 EUR	—	—	—	4,098 EUR	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation and amortisation expense [abstract]
Depreciation and amortisation expense	—	—	6,089,000 EUR	—	—	—	4,284,000 EUR	—
Other expenses, by nature	—	—	2,073 EUR	—	—	—	1,809 EUR	—
Disclosure of attribution of expenses by nature to their function [text block]	—	—	—	—	—	—	—	—
Disclosure of attribution of expenses by nature to their function [abstract]
Disclosure of attribution of expenses by nature to their function [line items]
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	- EUR	- EUR	5,891 EUR	5,891 EUR	6,010 EUR	- EUR	6,010 EUR	- EUR
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent	—	—	5,891 EUR	—	—	—	6,010 EUR	—